Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy

Back to Search
Print
Bookmark Trial

NCT00264875

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Phoenix, Arizona, 85023, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Peripheral Neuropathy, HIV Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Participation in the preceding A0081066 double-blind trial met the entry criteria for that trial and completed A0081066 study through visit 7

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Experienced serious adverse event during the A0081066 trial that was considered
related or possibly related to study medication by the investigator or sponsor


- non-compliant during A0081066 trial


- clinically significant or unstable medical condition both HIV-related and non-HIV
related including but not limited to, cardiac, pulmonary or hepatorenal disease that,
in the opinion of the investigator, would compromise participation in the study

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Peripheral Neuropathy, HIV InfectionsOpen Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy
NCT00264875
  1. Phoenix, Arizona
  2. Little Rock, Arkansas
  3. Los Angeles, California
  4. Los Angeles, California
  5. Sacramento, California
  6. San Diego, California
  7. San Francisco, California
  8. Stanford, California
  9. West Hollywood, California
  10. Denver, Colorado
  11. Miami, Florida
  12. Pensacola, Florida
  13. Safety Harbor, Florida
  14. Vero Beach, Florida
  15. West Palm Beach, Florida
  16. Atlanta, Georgia
  17. Chicago, Illinois
  18. Chicago, Illinois
  19. Baltimore, Maryland
  20. Boston, Massachusetts
  21. Springfield, Massachusetts
  22. Saint Louis, Missouri
  23. Saint Louis, Missouri
  24. New York, New York
  25. New York, New York
  26. New York, New York
  27. Rochester, New York
  28. Philadelphia, Pennsylvania
  29. Austin, Texas
  30. Dallas, Texas
  31. Dallas, Texas
  32. Dallas, Texas
  33. San Antonio, Texas
  34. Seattle, Washington
  35. Ponce,
  36. San Juan,
  37. San Juan,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy
Official Title  ICMJE An Open-Label, Extension Safety And Efficacy Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With Human Immunodeficiency Virus (HIV) Neuropathy
Brief Summary To evaluate the safety and efficacy of pregabalin in reducing neuropathic pain associated with HIV neuropathy
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Peripheral Neuropathy
  • HIV Infections
Intervention  ICMJE Drug: pregabalin
75mg BID, titrated up to 300mg according to individual response and tolerability
Study Arms  ICMJE Experimental: 1
Intervention: Drug: pregabalin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 24, 2008)		220
Original Enrollment  ICMJE
 (submitted: December 12, 2005)		300
Actual Study Completion Date  ICMJE February 2008
Actual Primary Completion Date February 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Participation in the preceding A0081066 double-blind trial met the entry criteria for that trial and completed A0081066 study through visit 7

Exclusion Criteria:

  • Experienced serious adverse event during the A0081066 trial that was considered related or possibly related to study medication by the investigator or sponsor
  • non-compliant during A0081066 trial
  • clinically significant or unstable medical condition both HIV-related and non-HIV related including but not limited to, cardiac, pulmonary or hepatorenal disease that, in the opinion of the investigator, would compromise participation in the study
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Puerto Rico,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00264875
Other Study ID Numbers  ICMJE A0081095
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date October 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP